RI-001 + RI-001 + RI-001
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Upper Respiratory Tract Infection
Conditions
Upper Respiratory Tract Infection, Lower Respiratory Tract Infection
Trial Timeline
Feb 1, 2008 → May 1, 2010
NCT ID
NCT00632463About RI-001 + RI-001 + RI-001
RI-001 + RI-001 + RI-001 is a phase 2 stage product being developed by ADMA Biologics for Upper Respiratory Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00632463. Target conditions include Upper Respiratory Tract Infection, Lower Respiratory Tract Infection.
What happened to similar drugs?
6 of 15 similar drugs in Upper Respiratory Tract Infection were approved
Approved (6) Terminated (1) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00632463 | Phase 2 | Completed |
Competing Products
20 competing products in Upper Respiratory Tract Infection